EyePoint PharmaceuticalsEYPT
EYPT
About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Employees: 144
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $5.09M | Put options by funds: $2.57M
4% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
6.52% less ownership
Funds ownership: 116.52% [Q2] → 110.0% (-6.52%) [Q3]
9% less funds holding
Funds holding: 150 [Q2] → 137 (-13) [Q3]
9% less capital invested
Capital invested by funds: $528M [Q2] → $479M (-$48.8M) [Q3]
33% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 33
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
194%
upside
Avg. target
$30
304%
upside
High target
$33
341%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz 24% 1-year accuracy 11 / 45 met price target | 341%upside $33 | Buy Initiated | 7 Jan 2025 |
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 62 / 156 met price target | 194%upside $22 | Buy Reiterated | 5 Dec 2024 |
Baird | 341%upside $33 | Outperform Maintained | 11 Nov 2024 |
Chardan Capital Daniil Gataulin 29% 1-year accuracy 10 / 34 met price target | 341%upside $33 | Buy Maintained | 8 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 week ago
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors.
Neutral
GlobeNewsWire
1 month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company's second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD).
Positive
Seeking Alpha
2 months ago
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Negative
Zacks Investment Research
2 months ago
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
Neutral
GlobeNewsWire
2 months ago
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 14,636,363 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock, at the public offering price of $11.00 per share. Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $161.0 million.
Neutral
GlobeNewsWire
2 months ago
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock at a public offering price of $11.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $140.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock are being sold by EyePoint. The closing of the offering is expected to occur on or about October 31, 2024, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,909,090 shares of EyePoint's common stock at the public offering price, less underwriting discounts and commissions.
Charts implemented using Lightweight Charts™